Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer

Download these slides from a live Webinar to gain expert insight on the new and emerging data on the optimal use of CDK4/6 and PI3K inhibitors for patients with HR+/HER2 breast cancer.

Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer

Matthew P. Goetz, MD
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 899 KB
Released: March 5, 2021

Acknowledgements

Produced in collaboration with
Supported by an educational grant from
Lilly

Related Content

Dr Yara Abdou discusses BRCA mutation testing and adjuvant therapy with olaparib in BRCA-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: May 17, 2022 Expired: May 16, 2023

Slideset from Dr Yara Abdou on adjuvant olaparib in BRCA1/2-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Released: May 17, 2022

Dr. Yara Abdou discusses Ki-67 testing and adjuvant abemaciclib in HR+/HER2-, node-positive, high-risk early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 12, 2022 Expired: May 11, 2023

Slideset from Dr. Yara Abdou on Ki-67 and adjuvant abemaciclib for HR+/HER2-, node-positive, high-risk EBC, from Clinical Care Options (CCO)

Yara Abdou, MD Released: May 12, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings